LeukemiaPhase 2NCT00049179
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
A Phase 2 study testing cytarabine and gemtuzumab ozogamicin in people with Leukemia, run by SWOG Cancer Research Network at 151 sites in United States.
Trial summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Leukemia
- What is being tested?
- cytarabine and gemtuzumab ozogamicin
- Type of treatment
- Injection or infusion
- How many people
- 33 participants
- Where
- 151 sitesUnited States
- Study dates
- Apr 2003to Oct 2010
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed acute myeloid leukemia (AML)
- FAB M1-2 or M4-7
- No blastic transformation of chronic myelogenous leukemia
- In first relapse after prior complete response
- Patients who relapsed after autologous or allogeneic bone marrow or peripheral blood stem cell transplantation are not eligible
- CD33 positive
- Prior myelodysplastic syndromes or secondary AML allowed
- Concurrent enrollment on SWOG-9007 (cytogenetics protocol)
- No clinical or documented CNS involvement with AML
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Zubrod 0-2
Life expectancy
- Not specified
Hematopoietic
- WBC no greater than 30,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST or ALT no greater than 1.5 times ULN
Renal
- Not specified
Cardiovascular
- No unstable cardiac arrhythmias
- No unstable angina
Other
- HIV negative
- No other malignancy within the past 5 years except for the following:
- Adequately treated basal cell or squamous cell skin cancer
- Carcinoma in situ of the cervix
- Adequately treated stage I or II cancer currently in complete remission
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- No prior gemtuzumab ozogamicin for AML
Chemotherapy
- Prior hydroxyurea to control high cell counts allowed
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- At least 4 weeks since prior investigational agents and recovered
Trial locations and contacts
151 sites in 1 country.
151 sites in 1 country
United States151 sites
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany, Georgia, 31703
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
Rose Ramer Cancer Clinic at Anderson Area Medical Center
Anderson, South Carolina, 29621
Randolph Hospital
Asheboro, North Carolina, 27203
Piedmont Hospital
Atlanta, Georgia, 30309
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Northside Hospital Cancer Center
Atlanta, Georgia, 30342
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342
WellStar Cobb Hospital
Austell, Georgia, 30106
Baton Rouge General Regional Cancer Center
Baton Rouge, Louisiana, 70806
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, 70809
St. Francis Hospital and Health Centers
Beech Grove, Indiana, 46107
St. Joseph Hospital Community Cancer Center
Bellingham, Washington, 98225
Alta Bates Comprehensive Cancer Center
Berkeley, California, 94705
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Deaconess Billings Clinic - Downtown
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Deaconess Billings Clinic Cancer Center
Billings, Montana, 59107
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Internal Medicine Associates of Bozeman
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Mills-Peninsula Health Services
Burlingame, California, 94010
St. James Community Hospital
Butte, Montana, 59701
St. Francis Medical Center
Cape Girardeau, Missouri, 63701
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233
Adena Regional Medical Center
Chillicothe, Ohio, 54601
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214
CCOP - Columbus
Columbus, Ohio, 43215
Grant Riverside Cancer Services
Columbus, Ohio, 43215
Mount Carmel West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
John Smith, Jr./Dalton McMichael Cancer Center at Morehead Memorial Hospital
Eden, North Carolina, 27288
Cancer Center of Kansas, P.A. - El Dorado
El Dorado, Kansas, 67042
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Gape Girardeau, Missouri, 63701
Legacy Mount Hood Medical Center
Glesham, Oregon, 97030
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Big Sky Oncology
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute
Great Falls, Montana, 59405
Marin Cancer Institute at Marin General Hospital
Greenbrae, California, 94904
Sutter Health Western Division Cancer Research Group
Greenbrae, California, 94904
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27401
St. Peter's Hospital
Helena, Montana, 59601
Veterans Affairs Medical Center - Hines
Hines, Illinois, 60141
Hematology Oncology Associates of Eastern Idaho
Idaho Falls, Idaho, 83404
Community Oncology Group - Independence
Independence, Ohio, 44131
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Kansas City, Kansas, 66160
CCOP - Kansas City
Kansas City, Missouri, 64131
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas - Kingman
Kingman, Kansas, 67068
Fairfield Medical Center
Lancaster, Ohio, 43130
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Southwest Medical Center
Liberal, Kansas, 67901
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Orange Regional Medical Center - Horton Campus
Middletown, New York, 10940
Middletown Regional Hospital
Middletown, Ohio, 45044
Eastern Montana Cancer Center
Miles City, Montana, 59301
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Community Medical Center
Missoula, Montana, 59801
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59802
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59802
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Cancer Care Center at Skagit Valley Hospital
Mount Vernon, Washington, 98273
Cancer Center at Medical Center of Louisiana - New Orleans
New Orleans, Louisiana, 70112
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Tulane Cancer Center
New Orleans, Louisiana, 70112
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
Orange, California, 92868
Cancer Center of Kansas, P.A. - Parsons
Parsons, Kansas, 67357
Comprehensive Cancer Center at Legacy Good Samaritan Hospital & Medical Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Institute of Oncology at Vilnius University
Portland, Oregon, 97227
Pratt Cancer Center of Kansas
Pratt, Kansas, 67124
Annie Penn Cancer Center
Reidsville, North Carolina, 27320
Southern Regional Medical Center
Riverdale, Georgia, 30274
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Cancer Center of Kansas - Salina
Salina, Kansas, 67042
Salina Regional Health Center
Salina, Kansas, 67401
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78209
Cancer Therapy and Research Center
San Antonio, Texas, 78229
University Hospital - San Antonio
San Antonio, Texas, 78229
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284
California Pacific Medical Center - California Campus
San Francisco, California, 94118
Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
Savannah, Georgia, 31403
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98104
Group Health Central Hospital
Seattle, Washington, 98104
Harborview Medical Center
Seattle, Washington, 98104
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98114
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195
Welch Cancer Center
Sheridan, Wyoming, 82801
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71101
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
Shreveport, Louisiana, 71130
Providence Cancer Institute at Providence Hospital - Southfield Campus
Southfield, Michigan, 48075
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29304
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
Regional Cancer Center at Memorial Medical Center
Springfield, Illinois, 62781-0001
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65802
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Mercy Medical Center Oncology Unit
Springfield, Ohio, 45504
Community Hospital of Springfield and Clark County
Springfield, Ohio, 45505
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
CCOP - Scott and White Hospital
Temple, Texas, 76508
Cancer Center at Stormont-Vail Regional Health Center
Topeka, Kansas, 66604
St. Francis Comprehensive Cancer Center
Topeka, Kansas, 66606
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Cancer Center at Southwest Washington Medical Center
Vancouver, Washington, 98668
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Central Washington Hospital
Wenatchee, Washington, 98801
Wenatchee Valley Clinic
Wenatchee, Washington, 98801
Mount Carmel Cancer Services at Mount Carmel St. Ann's Hospital
Westerville, Ohio, 43081
Associates in Womens Health
Wichita, Kansas, 67203
Cancer Center of Kansas, P.A.
Wichita, Kansas, 67208
Cancer Center of Kansas, P.A. - Wichita
Wichita, Kansas, 67214
CCOP - Wichita
Wichita, Kansas, 67214
Via Christi Cancer Center at Via Christi Regional Medical Center
Wichita, Kansas, 67214
Wesley Medical Center
Wichita, Kansas, 67214
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Cleveland Clinic - Wooster
Wooster, Ohio, 44691
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
Xenia, Ohio, 45385
Tod Children's Hospital - Forum Health
Youngstown, Ohio, 44501
Genesis - Good Samaritan Hospital
Zanesville, Ohio, 43701
About this study
Official title: A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML)
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die. Combining gemtuzumab ozogamicin with cytarabine may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining gemtuzumab ozogamicin with cytarabine in treating patients who have relapsed acute myeloid leukemia.
Read the detailed description
OBJECTIVES:
- Determine the safety and efficacy of gemtuzumab ozogamicin and cytarabine in patients with relapsed acute myeloid leukemia.
- Determine the frequency and severity of toxic effects of this regimen in CD33-positive patients.
- Determine, preliminarily, the prognostic significance of drug resistance phenotype, cytogenetics, and molecular genetic characteristics of patients treated with this regimen.
OUTLINE: This is a multicenter study.
- Induction: Patients receive gemtuzumab ozogamicin IV over at least 2 hours on days 1 and 8 and cytarabine IV continuously over days 1-7.
- Consolidation: Beginning between days 28 and 75, patients who achieve A1 bone marrow, B1 peripheral blood, and C1 extramedullary disease status receive one course of gemtuzumab ozogamicin and cisplatin as in induction chemotherapy.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.
PROJECTED ACCRUAL: A total of 30-55 patients will be accrued for this study within 10-28 months.
- Conditions
- Leukemia
- Being tested
- cytarabine, gemtuzumab ozogamicin
- Keywords
- adult acute monocytic leukemia (M5b), adult acute erythroid leukemia (M6), adult acute megakaryoblastic leukemia (M7), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4), adult acute monoblastic leukemia (M5a), recurrent adult acute myeloid leukemia, secondary acute myeloid leukemia, adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with 11q23 (MLL) abnormalities
- Medical subject headings
- Leukemia, Leukemia, Monocytic, Acute, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute, Congenital Abnormalities
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cytarabineDrug
ind and consol: 200 mg/m2/d continuous IV days 1-7
gemtuzumab ozogamicinDrug
ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
What is being measured
The primary outcome is the main question the study is designed to answer.
CR
Measured: After induction therapy is completed
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startApr 2003
- Primary completionDec 2005
- Study completionOct 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeukemiaStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 33 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- John E. Godwin, MD, MS, Study chair, Loyola University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00049179
- Sponsor's protocol ID
- S0117
- Other IDs
- S0117, U10CA032102
- Status last verified
- Mar 2015
- First submitted
- 12 Nov 2002
- Last updated
- 6 Mar 2015
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML)
- ClinicalTrials.gov ID
- NCT00049179
- Acronym / sponsor ID
- S0117
- Conditions
- Leukemia
- Keywords
- adult acute monocytic leukemia (M5b), adult acute erythroid leukemia (M6), adult acute megakaryoblastic leukemia (M7), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4), adult acute monoblastic leukemia (M5a), recurrent adult acute myeloid leukemia
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 33 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Apr 2003
- Primary completion
- Dec 2005 (actual)
- Study completion
- Oct 2010 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die. Combining gemtuzumab ozogamicin with cytarabine may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining gemtuzumab ozogamicin with cytarabine in treating patients who have relapsed acute myeloid leukemia.
Detailed description
OBJECTIVES:
- Determine the safety and efficacy of gemtuzumab ozogamicin and cytarabine in patients with relapsed acute myeloid leukemia.
- Determine the frequency and severity of toxic effects of this regimen in CD33-positive patients.
- Determine, preliminarily, the prognostic significance of drug resistance phenotype, cytogenetics, and molecular genetic characteristics of patients treated with this regimen.
OUTLINE: This is a multicenter study.
- Induction: Patients receive gemtuzumab ozogamicin IV over at least 2 hours on days 1 and 8 and cytarabine IV continuously over days 1-7.
- Consolidation: Beginning between days 28 and 75, patients who achieve A1 bone marrow, B1 peripheral blood, and C1 extramedullary disease status receive one course of gemtuzumab ozogamicin and cisplatin as in induction chemotherapy.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.
PROJECTED ACCRUAL: A total of 30-55 patients will be accrued for this study within 10-28 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cytarabineind and consol: 200 mg/m2/d continuous IV days 1-7 | Drug | – |
| gemtuzumab ozogamicinind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8 | Drug | – |
Primary outcome
CR
Time frame: After induction therapy is completed
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2015.
Related trials for Leukemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John E. Godwin, MD, MS study chair
Loyola University
151 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing cytarabine and gemtuzumab ozogamicin in people with Leukemia, run by SWOG Cancer Research Network at 151 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 151 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CR (time frame: After induction therapy is completed). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2015.